Spotify Apple Youtube

Category: Prevalence/Incidence

All Podcast Categories
S4-33.2 - Unmet Needs in the Primary Care Setting for Disease Identification

S4-33.2 – Unmet Needs in the Primary Care Setting for Disease Identification

Sven Francque and Ian Rowe join Jörn Schattenberg and Roger Green to discuss the presentations of interest from EASL Congress 2023. In this conversation, Ian points to a presentation on automated FIB-4 score calculation and e-reminders to detect advanced liver disease in patients with type 2 diabetes. The group goes on to explore big picture questions on the topic of disease identification and tease the differences between hepatology and private practices and management of a population-level disease.

July 22, 2023
S4-33 - EASL Congress: Nomenclature and More Compelling Presentations

S4-33 – EASL Congress: Nomenclature and More Compelling Presentations

Sven Francque and Ian Rowe join Jörn Schattenberg and Roger Green to discuss critical and/or compelling presentations and insights from the recently concluded EASL Congress in Vienna. The session focuses on new nomenclature and emerging stories around patient identification, NITs, fibrosis resolution and more.

July 19, 2023
S2-5 - Key Insights from the American Diabetes Association 83rd Scientific Sessions

S2-5 – Key Insights from the American Diabetes Association 83rd Scientific Sessions

Ken Cusi and Roger Green are joined by family practice researcher and KOL Eric Johnson and diabetologist and primary care KOL Jay Shubrook in a discussion around exciting news emerging from the ADA 83rd Scientific Sessions meeting. Layering in practical takeaways, the group explores their impressions from the meeting, the utility of FIB-4 as a frontline screening tool, guidelines and recommendations, therapeutic options both now and in the imminent future, and lastly the new nomenclature rollout for Fatty Liver disease.

July 13, 2023
S4-32 - Drug Development Stories from EASL and ADA: Part 1

S4-32 – Drug Development Stories from EASL and ADA: Part 1

Stephen Harrison and Jörn Schattenberg join Roger Green to discuss newly released Phase 3 MAESTRO-NASH data on resmetirom and the wider NASH therapeutic landscape, AI-assisted digital pathology, what the field understands about liver volume reduction, an increasing burden of cirrhosis and much more. This episode is packed with robust analysis and insights stemming from a busy past month at the EASL Congress and ADA Scientific Sessions meetings.

July 12, 2023
S4-30.3 - EASL Congress 2023: More Posters and Presentations

S4-30.3 – EASL Congress 2023: More Posters and Presentations

Hannes Hagström, Michelle Long, Rachel Zayas, Jeff McIntyre, Michael Betel and Roger Green get together for an in-depth wrap-up session on EASL Congress 2023. In this conversation each panelist revisits the posters and presentations they found compelling. As expected from such a diverse group, the discussion touches on a range of fascinating topics all worth consideration.

July 7, 2023
S4-30.1 - EASL Congress 2023: Nomenclature Rollout

S4-30.1 – EASL Congress 2023: Nomenclature Rollout

Hannes Hagström, Michelle Long, Rachel Zayas, Jeff McIntyre, Michael Betel and Roger Green get together for an in-depth wrap-up session on EASL Congress 2023. In this first of four conversations, the panelists share their initial impressions before diving into the implications of the new nomenclature rollout.

July 7, 2023
S4-29.2 - EASL Congress 2023: Challenges in Patient Screening and the “2nd Wave” of NASH Therapeutics

S4-29.2 – EASL Congress 2023: Challenges in Patient Screening and the “2nd Wave” of NASH Therapeutics

Surfing NASH conducted on-site coverage from EASL Congress 2023 in Vienna with Ian Rowe, Michael Betel, Jörn Schattenberg and Roger Green. In this conversation the group discusses a session that Jörn co-chaired on challenges in screening patients for fatty liver diseases. Notes touch on how time restrictions obstruct frontline treaters from offering both adequate screening and support lifestyle interventions simultaneously. The group goes on to consider the potential of dual agonists efinopegdutide and pemvidutide.

July 7, 2023
S4-27.3 - Abstract session - NAFLD: Clinical Aspects

S4-27.3 – Abstract session – NAFLD: Clinical Aspects

This conversation covers final thoughts on the anticipations of Ian Rowe, Jörn Schattenberg and Roger Green heading into EASL Congress 2023. The group primarily explores a session on NAFLD clinical aspects which provides practical presentations around tools available now for treating and managing patients with NASH.

June 17, 2023
S4-27.1 - Unpacking the Program with Ian Rowe and Jörn Schattenberg

S4-27.1 – Unpacking the Program with Ian Rowe and Jörn Schattenberg

This conversation with Ian Rowe, Jörn Schattenberg and Roger Green begins to unpack the rich EASL Congress 2023 program and explore in detail presentations of interest. Specifically, the group dives into anticipations around an abstract session around diagnostics and non-invasive assessment.

June 17, 2023
Stay In Touch
Apple Spotify Youtube

Sponsoring Partnerships

Sponsoring partnerships with SurfingMASH present a multifaceted avenue for companies seeking to amplify their brand presence and engage with targeted audiences.

Learn More